SCHEMBL2590961

SCHEMBL2590961

CCOC(=O)c1c(OCC)cc[nH]c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 3/20 0.46
HPGD P15428 1/20 0.46
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45
NUDT1 P36639 1/20 0.43
NPSR1 Q6W5P4 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
NR1H2 P55055 1/20 0.40
NR1H3 Q13133 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28559921 0.84 L3MBTL1 (0.41) KDM4EALDH1A1HPGDCA9GAA
SCHEMBL16386608 0.82 ALDH1A1 (0.57) KDM4EALDH1A1HPGDCA12CA1
SCHEMBL25068659 0.79 KDM4E (0.47) KDM4EALDH1A1HPGDCA12CA1
SCHEMBL7572546 0.79 KDM4E (0.47) KDM4EALDH1A1HPGDCA12CA1
SCHEMBL10972496 0.75 IGF1R (0.40) KDM4EALDH1A1HPGDGAAKMT2A
SCHEMBL7416822 0.74 KMT2A (0.52) KDM4EALDH1A1HPGDCA12CA1
SCHEMBL27294436 0.73 PRKCZ (0.54) KDM4EALDH1A1HPGDCA12CA1
SCHEMBL14351829 0.72 SMN1; SMN2 (0.49) KDM4EALDH1A1HPGDCA12CA1
SCHEMBL6219929 0.72 ALDH1A1 (0.56) KDM4EALDH1A1HPGDCA12CA1
SCHEMBL22923880 0.72 ALDH1A1 (0.45) KDM4EALDH1A1HPGDCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132158-A1 PHENYL OXY AMIDE KINASE INHIBITORS THE TRANSLATIONAL GENOMICS RESEARCH INST (US) 2026-05-14 US disclosed
US-12202835-B2 Substituted aromatic ring-linked dioxinoquinazolines and dioxinoquinolines as kinase inhibitors BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2025-01-21 US disclosed
US-20240293386-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR LG CHEM, LTD. (KR) 2024-09-05 US disclosed
US-20240174666-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC. (US) 2024-05-30 US disclosed
US-20240150325-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITORS LG CHEM, LTD. (KR) 2024-05-09 US disclosed
WO-2024077057-A1 PHENYL OXY AMIDE KINASE INHIBITORS THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2024-04-11 WO disclosed
EP-4332106-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR LG Chem, Ltd. (KR) 2024-03-06 EP disclosed
CN-117355533-A Novel compounds as protein kinase inhibitors 株式会社LG化学 2024-01-05 CN disclosed
EP-3843850-B1 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC (US) 2023-11-15 EP disclosed
EP-4273140-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR Lg Chem, Ltd. (KR) 2023-11-08 EP disclosed
US-8558000-B2 4-pyridinone compounds and their use for cancer BRISTOL-MYERS SQUIBB COMPANY (US) 2013-10-15 US disclosed
US-8558000-B2 4-pyridinone compounds and their use for cancer BRISTOL-MYERS SQUIBB COMPANY (US) 2013-10-15 US disclosed
US-8558000-B2 4-pyridinone compounds and their use for cancer BRISTOL-MYERS SQUIBB COMPANY (US) 2013-10-15 US disclosed
WO-2013078295-A2 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2013-05-30 WO disclosed
EP-2563773-A1 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES Deciphera Pharmaceuticals, LLC (US) 2013-03-06 EP disclosed
US-20120172382-A1 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC. (US) 2012-07-05 US disclosed
WO-2011139891-A1 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES DECIPHERA PHARMACEUTICALS, LLC (US) 2011-11-10 WO disclosed
EP-2235001-A1 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER Bristol-Myers Squibb Company (US) 2010-10-06 EP disclosed
WO-2009094427-A1 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER BRISTOL-MYERS SQUIBB COMPANY (US) 2009-07-30 WO disclosed
WO-2009094427-A1 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER BRISTOL-MYERS SQUIBB COMPANY (US) 2009-07-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150325-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITORS MAP3K20, SBK3, MAPKAPK2 KDM4E 1700/4885ALDH1A1 4608/4885HPGD 3990/4885
US-20120172382-A1 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES MKI67, TYMP, CCNA1 KDM4E 1899/4885ALDH1A1 250/4885HPGD 150/4885
US-20240174666-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES RET, MERTK, MET KDM4E 951/4885ALDH1A1 2323/4885HPGD 4005/4885
US-12202835-B2 Substituted aromatic ring-linked dioxinoquinazolines and dioxinoquinolines as kinase inhibitors MERTK, AXL, TYRO3 KDM4E 1155/4885ALDH1A1 2489/4885HPGD 4446/4885
US-20240293386-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR MAP3K20, SBK3, MAPKAPK2 KDM4E 1510/4885ALDH1A1 4634/4885HPGD 4106/4885
US-20260132158-A1 PHENYL OXY AMIDE KINASE INHIBITORS RAF1, CNKSR1, PHKG1 KDM4E 1492/4885ALDH1A1 2783/4885HPGD 3096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.